Research ArticleOriginal Article
Open Access

Efficacy and safety of rituximab in patients with multiple sclerosis

An observational study at a tertiary center in Makkah, Saudi Arabia

Yassir M. Almatrafi, Mohammed A. Babakkor, Muhammed Irfan, Ebaa T. Samkari, Waleed M. Alzahrani, Doaa K. Mohorjy, Sarmad Zahoor, Muhammad T. Farooq and Hafiz M. Sajid Jehangir
Neurosciences Journal April 2022, 27 (2) 65-70; DOI: https://doi.org/10.17712/nsj.2022.2.20210122

References

  1. 1.↵
    1. AlJumah M,
    2. Bunyan R,
    3. Al Otaibi H,
    4. Al Towaijri G,
    5. Karim A,
    6. Al Malik Y, et al.
    Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. BMC Neurology 2020; 20: 1–7.
    OpenUrl
  2. 2.↵
    1. Dobson R,
    2. Giovannoni G.
    Multiple sclerosis – a review. Eur J Neurol 2019; 26: 27–40.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Castillo-Trivino T,
    2. Braithwaite D,
    3. Bacchetti P,
    4. Waubant E.
    Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013; 8: e66308.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Milo R.
    Therapies for multiple sclerosis targeting B cells. Croat Med J 2019; 60: 87–98.
    OpenUrl
  5. 5.↵
    1. Molnarfi N,
    2. Schulze-Topphoff U,
    3. Weber MS,
    4. Patarroyo JC,
    5. Prod’homme T,
    6. Varrin-Doyer M, et al.
    MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013; 210: 2921–2937.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Castro-Borrero W,
    2. Graves D,
    3. Frohman TC,
    4. Flores AB,
    5. Hardeman P,
    6. Logan D, et al.
    Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012; 5: 205–220.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Salzer J,
    2. Svenningsson R,
    3. Alping P,
    4. Novakova L,
    5. Björck A,
    6. Fink K, et al.
    Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 2016; 87: 2074–2081.
    OpenUrl
  8. 8.↵
    1. Capasso N,
    2. Nozzolillo A,
    3. Scalia G,
    4. Lanzillo R,
    5. Carotenuto A,
    6. De Angelis M, et al.
    Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis. Mult Scler Relat Disord 2021; 49:102802.
    OpenUrl
  9. 9.↵
    1. Hauser SL,
    2. Waubant E,
    3. Arnold DL,
    4. Vollmer T,
    5. Antel J,
    6. Fox RJ, et al.
    B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Naismith RT,
    2. Piccio L,
    3. Lyons JA,
    4. Lauber J,
    5. Tutlam NT,
    6. Parks BJ, et al.
    Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010; 74: 1860–1867.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Yamout BI,
    2. El-Ayoubi NK,
    3. Nicolas J,
    4. El Kouzi Y,
    5. Khoury SJ,
    6. Zeineddine MM.
    Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. J Immunol Res 2018; 2018: 9084759.
    OpenUrl
  12. 12.↵
    1. Airas L,
    2. Nylund M,
    3. Mannonen I,
    4. Matilainen M,
    5. Sucksdorff M,
    6. Rissanen E.
    Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. Mult Scler Relat Disord 2020; 40: 101980.
    OpenUrl
  13. 13.↵
    1. Bellinvia A,
    2. Prestipino E,
    3. Portaccio E,
    4. Razzolini L,
    5. Fonderico M,
    6. Fratangelo R, et al.
    Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. Neurol Sci 2020; 41: 2939–2945.
    OpenUrl
  14. 14.↵
    1. Barra ME,
    2. Soni D,
    3. Vo KH,
    4. Chitnis T,
    5. Stankiewicz JM.
    Experience with long-term rituximab use in a multiple sclerosis clinic. Multiple Sclerosis Journal – Experimental, Translational and Clinical 2016; 2: 2055217316672100.
    OpenUrl
  15. 15.↵
    1. Scotto R,
    2. Reia A,
    3. Buonomo AR,
    4. Moccia M,
    5. Viceconte G,
    6. Pisano E, et al.
    Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. Expert Opin Drug Saf 2021; 20: 925–936.
    OpenUrl
  16. 16.↵
    1. Granqvist M,
    2. Boremalm M,
    3. Poorghobad A,
    4. Svenningsson A,
    5. Salzer J,
    6. Frisell T, et al.
    Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 2018; 75: 320–327.
    OpenUrl
  17. 17.↵
    1. Polman CH,
    2. Reingold SC,
    3. Banwell B,
    4. Clanet M,
    5. Cohen JA,
    6. Filippi M, et al.
    Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Kurtzke JF.
    Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Hauser SL.
    The Charcot Lecture | beating MS: a story of B cells, with twists and turns. Mult Scler 2015; 21: 8–21.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Mazdeh M,
    2. Khamseh M,
    3. Taheri M,
    4. Ghafouri-Fard S.
    Effect of rituximab on Expanded Disability Status Scale and relapse rate in multiple sclerosis patients. J Mol Neurosci 2020; 70: 1165–1168.
    OpenUrl
  21. 21.↵
    1. Scotti B,
    2. Disanto G,
    3. Sacco R,
    4. Guigli M,
    5. Zecca C,
    6. Gobbi C.
    Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PloS One 2018; 13: e0197415.
    OpenUrl
  22. 22.↵
    1. Alcalá C,
    2. Gascón F,
    3. Pérez-Miralles F,
    4. Gil-Perotín S,
    5. Navarré A,
    6. Boscá I,
    7. Coret F, et al.
    Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol 2018; 265: 1690–1697.
    OpenUrl
  23. 23.↵
    1. Clifford DB,
    2. Ances B,
    3. Costello C,
    4. Rosen-Schmidt S,
    5. Andersson M,
    6. Parks D, et al.
    Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68: 1156–1164.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Sikkema T,
    2. Schuiling WJ,
    3. Hoogendoorn M.
    Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma. BMJ Case Rep 2013; 2013: bcr2012008142.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Arad U,
    2. Tzadok S,
    3. Amir S,
    4. Mandelboim M,
    5. Mendelson E,
    6. Wigler I, et al.
    The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29: 1643–1648.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section